No Adverse Effects on Periarticular Tissue by Intra-articular Vitamin D analogue Calcipotriol in a Reduced-Dose Zymosan-Induced Arthritis Model in Rats

Basic Clin Pharmacol Toxicol. 2022 Nov 18. doi: 10.1111/bcpt.13815. Online ahead of print.ABSTRACTCalcipotriol, a vitamin D analogue, is an antiproliferative and anti-inflammatory drug currently used in psoriasis. Here, our aim was to analyse the safety of calcipotriol for cartilage and bone in alleviated-dose (0.1mg instead of usual ≥1mg dose) zymosan-induced arthritis in rats. Theoretically, high doses of vitamin D or analogues could have detrimental effects on bone or cartilage. The rats were divided into four groups: vehicle (n=9), dexamethasone 0.1 mg/kg (n=9), calcipotriol 0.1 mg/kg (n=8) and negative control (n=10) with no injections. Arthritic rats were given PBS injections to left knees as a control. After euthanasia on day 8, all knees were imaged with micro-computed tomography for surface lesions and decalcified for histological analyses. Contrary to our expectations, no significant changes could be observed in the tomography data and histological scores among the three treatment groups or between the vehicle-treated and non-arthritic group. Calcipotriol did not cause adverse effects on cartilage or subchondral bone within a week, suggesting that it could be safely used in local treatment of arthritis. The alleviated model caused synovitis with local and systemic inflammatory response without cartilage erosions, which might be useful in studying self-limiting synovitis where cartilage or bone effects are not of primary interest.PMID:36398969 | DOI:10.1111/bcpt.13...
Source: Cancer Control - Category: Cancer & Oncology Authors: Source Type: research